Please join us to meet our department chairs, residency program directors, faculty, fellows, and residents. You will learn about opportunities to train at our nationally-ranked hospitals while caring for a diverse patient population in St. Louis. You will gain a greater appreciation of our commitment to high quality, culturally appropriate care and health equity.
Importance of Identifying Etiology in Pediatric Stroke: Kristin Guilliams, MD, MSCI (Links to an external site)
Although it is commonly thought of as a disease amongst the elderly, it is important to recognize the impacts of stroke in pediatric settings. Given the occurrence at a younger age, with potential long-term effects on disability, some argue stroke may be more detrimental in the pediatric population. In both populations, acute stroke management is […]
57 Neurology faculty recognized on 2023 Castle Connolly Top Doctors® and Rising Stars lists
The Department of Neurology is pleased to announce 57 of our faculty members have been selected for the 2023 Castle Connolly Top Doctors® and Rising Stars lists. We are proud of our physicians for their hard work and dedication to their patients each and every day. Each year, Castle Connolly uses a merit-based system to […]
How do toxic proteins accumulate in Alzheimer’s and other diseases? (Links to an external site)
Under normal circumstances, tau protein is part of the brain’s infrastructure, important for stabilizing neurons into their proper shapes. But sometimes tau gets knotted up into tangles and turns toxic, injuring brain tissue and causing tauopathies, a group of brain diseases characterized by problems with learning, memory and movement. Alzheimer’s disease is the most common […]
Understanding the Varying Uses of Thrombolysis in Pediatric Stroke Settings: Kristin Guilliams, MD, MSCI (Links to an external site)
Ischemic stroke in the pediatric population is rare; however, stroke in children in the acute setting can be missed because of its low prevalence. Care for acute pediatric strokes involves determining the most likely etiology in a timely manner, understanding available resources, and making the best choice based on the information at hand, according to […]
Blood-based biomarkers for treatment monitoring in Alzheimer’s disease (Links to an external site)
Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, discusses the promise of blood-based biomarkers for treatment monitoring. Data has been presented on plasma phosphorylated-tau 217 (p-tau217) as a method to monitor the effects of lecanemab and donanemab. This research is investigating if medication discontinuation is feasible if p-tau217 […]
What to know about the new Alzheimer’s drug Leqembi (Links to an external site)
The Food and Drug Administration (FDA) recently gave full approval to Leqembi (lecanemab) for patients in the early stages of Alzheimer’s disease. Physicians and researchers at Washington University School of Medicine’s Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) in St. Louis were involved in the clinical trials evaluating Leqembi, in which they enrolled […]
St. Louis has highest Alzheimer’s rate in Missouri, with more than 1 in 10 adults affected (Links to an external site)
The city of St. Louis has the highest rate of Alzheimer’s dementia cases in Missouri, and new evidence from Washington University’s School of Medicine shows that social factors like income, race and education play a role in access to treatment and diagnosis. The new observational study, focused on the Washington University Memory Diagnostic Center, showed […]
Cognitive function in Down syndrome-associated Alzheimer’s focus of grant (Links to an external site)
Nearly every person with Down syndrome eventually develops Alzheimer’s disease, yet people with the syndrome routinely are excluded from Alzheimer’s clinical trials, as the cognitive assessment tools designed for the general population often are inappropriate for people with developmental disabilities. Consequently, nobody knows whether the new Alzheimer’s therapeutics hitting the market will work for people […]
Study defines disparities in memory care (Links to an external site)
Patients who live in less affluent neighborhoods and those from underrepresented racial or ethnic groups are less likely than others to receive specialized care for dementia, including Alzheimer’s disease, a new study from Washington University School of Medicine in St. Louis indicates. Further, the research shows that Black people are more likely than white people […]